Researchers hope to develop test that could detect early changes in blood flow to heart
A Duke Health pilot project suggests that in the near future, a blood test could show whether arteries carrying blood to the heart are narrow or blocked, a risk factor for heart disease.
According to the 40-person study published in the journal PLOS ONE, emergency patients who underwent a treadmill stress test and showed signs of decreased blood flow to the heart also had changes in five metabolites in their blood within two hours.
A control group of patients with normal stress tests did not show the same metabolite changes.
All study subjects had gone to the emergency department with symptoms of coronary disease, such as chest, jaw and shoulder pain.
The researchers hope a larger study could confirm that acute changes in these fatty acid and amino acid metabolites, which are energy sources for cells, could be an early biological indicator of restricted blood flow that could complement or even replace current tests.
“Cardiologists do a stress test to determine who’s at risk for having heart disease,” said lead author Alexander T. Limkakeng Jr., M.D., lead author of the study and an associate professor of emergency medicine at Duke. “It guides them on whether they need a more invasive study like a catheterization. Augmenting the imaging of a stress test with metabolite biomarkers could make that process more accurate or more efficient.”
Previous research has suggested that metabolites could indicate heart disease, but scientists have yet to uncover the specific metabolomic signature to look for. For the Duke study, scientists evaluated the presence of more than 60 chemicals or compounds in the blood to identify the five specific metabolites that appeared to change in patients with abnormal cardiac stress tests.
The researchers hope to begin a larger study to further test this approach to detecting coronary artery disease, they said.
The Latest on: Metabolite biomarkers
via Google News
The Latest on: Metabolite biomarkers
- Blood biomarkers can help us to customize our nutritional preferences: Max Kushniron January 9, 2020 at 6:33 pm
Every metabolite, every process that is happening in our bodies is reflected in our ... to know more about the trends in precision nutrition and how blood biomarkers can play a big role in deciphering ...
- A Biological Solution to the Mystery of Methane on Marson January 9, 2020 at 5:55 pm
Methane, which can be a biomarker—or indicator of life—on Earth ... single-celled microorganisms similar to bacteria that live in low-oxygen environments and produce methane as a result of their ...
- Applied Therapeutics Up on Positive Galactosemia Study Dataon January 9, 2020 at 4:12 pm
soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.
- Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Studyon January 9, 2020 at 11:31 am
The firm stated that the ACTION study is a double-blind trial evaluating the effects of AT-007 in healthy adult Galactosemia patients, and noted that the "key biomarker outcome of the study was ...
- Agent 007’s efficacy in galactosemia no secret; ATI Bond for meeting with FDAon January 8, 2020 at 3:27 pm
The key biomarker outcome of the study was reduction in galactitol, an aberrant toxic metabolite of galactose that’s formed by aldose reductase, and AT-007 turned up a statistically significant and ...
- Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestoneson January 8, 2020 at 5:00 am
This study, which is being conducted at 18 U.S. medical centers, is assessing the impact of AXA1125/AXA1957 on safety, tolerability and physiology, as measured by a comprehensive panel of imaging and ...
- Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patientson January 8, 2020 at 3:00 am
The key biomarker outcome of the study was reduction in galactitol, an aberrant toxic metabolite of galactose, formed by Aldose Reductase in Galactosemia patients. AT-007 treatment resulted in a ...
- Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Worldwide: Market Dynamics And Trends, Efficiencies Forecast 2024on January 7, 2020 at 10:35 pm
In the last several years, global market of Commercializing Biomarkers in Therapeutic and Diagnostic Applications developed rapidly, with an average growth rate of 8.49%. In 2015, the consumables ...
- Selecting likely causal risk factors from high-throughput experiments using multivariable Mendelian randomizationon January 7, 2020 at 2:18 am
We illustrate MR-BMA by analysing publicly-available summarized data on metabolites to prioritise likely causal biomarkers for age-related macular degeneration. Multivariable MR is an extension of ...
- Binge drinking linked to heart damage, study findson January 6, 2020 at 5:52 am
They found that heavy drinking was associated with increased levels of blood biomarkers that signify harm to heart tissue ... Second, alcohol can directly affect heart muscle by causing changes in its ...
via Bing News